Hughes, Gareth

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., et al. (2010) · Cancer Research

PI3K/AKT/mTOR signaling in cancerAutophagy in Disease and Therapy

Cited by 812

The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy

Greene, J., Nguyen, A., Bagby, S. M., Jones, G. N., Tai, W., Quackenbush, K. S., Schreiber, A., Messersmith, W. A., Devaraj, K. M., Blatchford, P., et al. (2017) · Oncotarget

DNA Repair MechanismsCancer therapeutics and mechanisms

Cited by 26